At week 56, mean blood pressure was generally unchanged from baseline for Contrave patients compared to placebo patients, who tended to experience a slight decrease (approximately 2 mm Hg) from baseline. Contrave treatment did not appear to disrupt the normal circadian pattern of blood pressure. There was a slight increase in pulse (approximately 1 beat per minute) in Contrave patients compared to placebo patients, whose pulse was generally unchanged. There were no meaningful treatment effects on ECGs or laboratory measures including liver function tests. Treatment with Contrave was not associated with increases in symptoms of depression or suicidal ideation.
"The data are remarkably consistent across the COR program, giving us greater confidence that Contrave has the potential to help obese patients, even those with diabetes, to initiate and sustain weight loss and improve their health," said Dr. Ken Fujioka, Lead Investigator, Director of Nutrition and Metabolic Research, Scripps Clinic. "These results mark the beginning of an exciting new era in the treatment of the global obesity epidemic where drug therapies may play an increasingly important role."
The Company has scheduled a conference call today, July 20, at 8:00 a.m. Eastern Time to discuss further details from these trials. The live call may be accessed by calling 1-800-561-2813, (domestic) 617-614-3529 (international); meeting code: 14007929. The webcast can be accessed live on the investor relations section of the Company's w
|SOURCE Orexigen Therapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved